{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T13:45:27Z","timestamp":1793281527747,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,6,5]],"date-time":"2017-06-05T00:00:00Z","timestamp":1496620800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s40264-017-0543-0","type":"journal-article","created":{"date-parts":[[2017,6,5]],"date-time":"2017-06-05T06:18:34Z","timestamp":1496643514000},"page":"771-781","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":164,"title":["Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8649-9943","authenticated-orcid":false,"given":"Lauren","family":"Hirsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaeun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Bresee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Jette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Patten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Pringsheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,5]]},"reference":[{"issue":"2","key":"543_CR1","first-page":"75","volume":"54","author":"M Horn","year":"2012","unstructured":"Horn M, Procyshyn R, Warburton W, Tregillus V, Cavers B, Davidson J, et al. Prescribing second-generation antipsychotic medications: practice guidelines for general practitioners. BCMJ. 2012;54(2):75\u201382.","journal-title":"BCMJ"},{"key":"543_CR2","unstructured":"Maglione M, Maher A, Hu J, Wang Z, Shanman R, Shekelle P, et al. Off-label use of atypical antipsychotics: an update. Rockville, MD: Agency for Healthcare Research and Quality; 2011. Contract No.: 11-EHC087."},{"issue":"3","key":"543_CR3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/070674370104600308","volume":"46","author":"RS McIntyre","year":"2001","unstructured":"McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, type 2 diabetes, and lipid abnormalities. Can J Psychiatry. 2001;46(3):273\u201381.","journal-title":"Can J Psychiatry"},{"issue":"9896","key":"543_CR4","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Compartive efficacy and tolerability of 15 antipsychotics drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951\u201362.","journal-title":"Lancet"},{"issue":"1","key":"543_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eurpsy.2013.08.001","volume":"29","author":"C Schneider","year":"2014","unstructured":"Schneider C, Corrigall R, Hayes D, Kyriakopoulos M, Frangou S. Systematic review of the efficacy and tolerability of clozapine in the treatment of youth with early onset schizophrenia. Eur Psychiatry. 2014;29(1):1\u201310.","journal-title":"Eur Psychiatry"},{"issue":"11","key":"543_CR6","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","volume":"156","author":"D Allison","year":"1999","unstructured":"Allison D, Mentore J, Heo M, Chandler L, Cappelleri J, Infante M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686\u201396.","journal-title":"Am J Psychiatry"},{"issue":"2\u20133","key":"543_CR7","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","volume":"123","author":"C RummelKluge","year":"2010","unstructured":"RummelKluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos C, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotisc in the treatment of schizophrenia: a systematic review and meta analysis. Schizophr Res. 2010;123(2\u20133):225\u201333.","journal-title":"Schizophr Res"},{"key":"543_CR8","doi-asserted-by":"publisher","unstructured":"Khanna P, Suo T, Komossa K, Ma H, Rummel-Kluge C, El-Sayeh HG, Leucht S, Xia J. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2014;(1):CD006569. doi: 10.1002\/14651858.CD006569.pub5 .","DOI":"10.1002\/14651858.CD006569.pub5"},{"issue":"5","key":"543_CR9","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.pnpbp.2011.03.022","volume":"35","author":"NY Lee","year":"2011","unstructured":"Lee NY, Kim SH, Jung DC, Kim EY, Yu HY, Sung KH, et al. The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(5):1273\u20138.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"543_CR10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/JCP.0b013e31802e5126","volume":"27","author":"C Reist","year":"2007","unstructured":"Reist C, Mintz J, Albers L, Jamal M, Szabo S, Ozdemir V. Second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia: an observational pharmacoepidemiology study from 1988 to 2002. J Clin Psychopharmacol. 2007;27(1):46\u201351.","journal-title":"J Clin Psychopharmacol"},{"key":"543_CR11","unstructured":"Effective Practice and Organisation of Care (EPOC). Data extraction and management. EPOC Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health Services; 2013. Available at: http:\/\/epoc.cochrane.org\/epoc-specific-resources-review-authors ."},{"key":"543_CR12","unstructured":"Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011."},{"key":"543_CR13","unstructured":"Wells G, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle\u2013Ottawa Scale for assessing the quality of nonrandomized studies in meta-analysis. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp . Accessed 1 May 2016."},{"issue":"10","key":"543_CR14","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jclinepi.2008.10.009","volume":"62","author":"B Shea","year":"2009","unstructured":"Shea B, Hamel C, Wells G, Bouter L, Kristjansson E, Grimshaw J, et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic review. J Clin Epidemiol. 2009;62(10):1013\u201320.","journal-title":"J Clin Epidemiol"},{"issue":"Suppl 1","key":"543_CR15","first-page":"1","volume":"19","author":"J Newcomer","year":"2005","unstructured":"Newcomer J. Second-generation (atypical) antipsychotics and metabolic effects. CNS Drugs. 2005;19(Suppl 1):1\u201393.","journal-title":"CNS Drugs"},{"issue":"4","key":"543_CR16","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1345\/aph.1G564","volume":"40","author":"DI Brixner","year":"2006","unstructured":"Brixner DI, Said Q, Corey-Lisle PK, Tuomari AV, L\u2019Italien GJ, Stockdale W, et al. Naturalistic impact of second-generation antipsychotics on weight gain. Ann Pharmacother. 2006;40(4):626\u201332.","journal-title":"Ann Pharmacother"},{"issue":"56","key":"543_CR17","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0895-4356(02)00588-7","volume":"2002","author":"J Buse","year":"2003","unstructured":"Buse J, Cavazzoni P, Hornbuckle K, Hutchins D, Breier A, Jovanovic L. A retrospective cohort study of Type 2 Diabetes and antipsychotic treatment in the United States. J Clin Epidemiol. 2003;2002(56):164\u201370.","journal-title":"J Clin Epidemiol"},{"key":"543_CR18","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.euroneuro.2005.11.002","volume":"16","author":"C Carlson","year":"2006","unstructured":"Carlson C, Hornbuckle K, DeLisle F, Kryzhanovskaya L, Breier A, Cavazzoni P. Type 2 Diabetes and antipsychotic treatment in the United Kingdom. Eur Neuropsychopharmacol. 2006;16:366\u201375.","journal-title":"Eur Neuropsychopharmacol"},{"key":"543_CR19","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.4088\/JCP.v63n1208","volume":"63","author":"J Caro","year":"2002","unstructured":"Caro J, Ward A, Levinton C, Robinson K. The risk of diabetes during olanzapine use compared with risperidione use: a retrospective database analysis. J Clin Psychiatry. 2002;63:1135\u20139.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"543_CR20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/wps.20187","volume":"14","author":"C Correll","year":"2015","unstructured":"Correll C, Joffe B, Rosen L, Sullivan T, Joffe R. Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepresseant use in a non-elderly adult sample: results from a claims-based inception cohort study. World Psychiatry. 2015;14(1):56\u201363.","journal-title":"World Psychiatry"},{"issue":"4","key":"543_CR21","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/YIC.0b013e32832d6c18","volume":"24","author":"EJ Duncan","year":"2009","unstructured":"Duncan EJ, Woolson SL, Hamer RM, Dunlop BW. Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population. Int Clin Psychopharmacol. 2009;24(4):204\u201313.","journal-title":"Int Clin Psychopharmacol"},{"issue":"8","key":"543_CR22","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1592\/phco.23.8.1037.32876","volume":"23","author":"M Fuller","year":"2003","unstructured":"Fuller M, Shermock K, Secic M, Grogg A. Comparative study of the development of type 2 diabetes in patients taking risperidone and olanzapine. Pharmacotherapy. 2003;23(8):1037\u201343.","journal-title":"Pharmacotherapy"},{"issue":"10","key":"543_CR23","doi-asserted-by":"crossref","first-page":"920","DOI":"10.4088\/JCP.v63n1010","volume":"63","author":"FD Gianfrancesco","year":"2002","unstructured":"Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RH, Nasrallah HA. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry. 2002;63(10):920\u201330.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"543_CR24","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1192\/bjp.bp.109.076935","volume":"197","author":"LV Kessing","year":"2010","unstructured":"Kessing LV, Thomsen AF, Mogensen UB, Andersen M. Treatment with antipsychotics and the risk of diabetes in clincial practice. Br J Psychiatry. 2010;197(4):266\u201371.","journal-title":"Br J Psychiatry"},{"issue":"4","key":"543_CR25","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/070674370905400408","volume":"54","author":"S Kisely","year":"2009","unstructured":"Kisely S, Cox M, Campbell LA, Cooke C, Gardner D. An epidemiologic study of psychotropic medication and obesity-related chronic illnesses in older psychiatric patients. Can J Psychiatry. 2009;54(4):269\u201374.","journal-title":"Can J Psychiatry"},{"issue":"5","key":"543_CR26","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/08039488.2011.565799","volume":"65","author":"K Krane-Gartiser","year":"2011","unstructured":"Krane-Gartiser K, Breum L, Glumrr C, Linneberg A, Madsen M, Koster A, et al. Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics. Nord J Psychiatry. 2011;65(5):345\u201352.","journal-title":"Nord J Psychiatry"},{"issue":"6","key":"543_CR27","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/01.nmd.0000165292.11527.16","volume":"193","author":"EA Miller","year":"2005","unstructured":"Miller EA, Leslie DL, Rosenheck RA. Incidence of new-onset Type 2 Diabetes among patients receiving atypical neuroleptics in the treatment of mental illness: evidence from a privately insured population. J Nerv Ment Dis. 2005;193(6):387\u201395.","journal-title":"J Nerv Ment Dis"},{"issue":"4","key":"543_CR28","doi-asserted-by":"publisher","first-page":"e150285","DOI":"10.1001\/jamapediatrics.2015.0285","volume":"169","author":"DM Rubin","year":"2015","unstructured":"Rubin DM, Kreider AR, Matone M, Huang YS, Feudtner C, Ross ME, Localio AR. Risk for incident diabetes mellitus following initiation of second-generation antipsychotics among Medicaid-enrolled youths. JAMA Pediatr. 2015;169(4):e150285. doi: 10.1001\/jamapediatrics.2015.0285 .","journal-title":"JAMA Pediatr."},{"issue":"1","key":"543_CR29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00004850-200501000-00007","volume":"20","author":"E Sacchetti","year":"2005","unstructured":"Sacchetti E, Turrina C, Parrinello G, Brignoli O, Stefanini G, Mazzaglia G. Incidence of diabetes in a general practice population: a database cohort study on the relationship with haloperidol, olanzapine, risperidone or quetiapine exposure. Int Clin Psychopharmacol. 2005;20(1):33\u20137.","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"543_CR30","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.4088\/JCP.14m08996","volume":"76","author":"S Skrede","year":"2015","unstructured":"Skrede S, Tvete IF, Tanum L, Steen VM, Bramness JG. Incident users of antipsychotic agents and future use of cholesterol-lowering drugs: an observational, pharmacoepidemiologic study. J Clin Psychiatry. 2015;76(1):e111\u20136.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"543_CR31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","volume":"80","author":"J McEvoy","year":"2005","unstructured":"McEvoy J, Meyer J, Goff D, Nasrallah HA, Davis S, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):19\u201332.","journal-title":"Schizophr Res"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-017-0543-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-017-0543-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-017-0543-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T18:28:34Z","timestamp":1692815314000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-017-0543-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,5]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["543"],"URL":"https:\/\/doi.org\/10.1007\/s40264-017-0543-0","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,5]]}}}